Get the Stockscreener App
0.00
100.00%
-1.71
Aptose Biosciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
See More
Previous Close:
$1.71
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$10.59M
Revenue:
-
Net Income/Loss:
$-35.80M
P/E Ratio:
0.00
EPS:
-2.97
Net Cash Flow:
$-37.18M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$36.30
Aptose Biosciences Inc Stock (APTO) Company Profile
Name
Aptose Biosciences Inc
Sector
Industry
Phone
310-849-8060
Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Compare APTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 10.59M | 0 | -35.80M | -37.18M | -2.97 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Feb-20-20 | Initiated | Maxim Group | Buy |
| Feb-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | Piper Sandler | Overweight |
| Mar-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Nov-16-18 | Initiated | B. Riley FBR | Buy |
| Dec-13-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-07-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-08-17 | Initiated | Rodman & Renshaw | Neutral |
View All
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
(APS) Market Performance Analysis (APS:CA) - news.stocktradersdaily.com
In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML - insights.citeline.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Aptose Biosciences Inc. - Baystreet.ca
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial for AML Treatment - TipRanks
Aptose Provides Clinical Update for Tuspetinib-based Triple Drug Therapy in Tuscany Trial - marketscreener.com
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial - The Manila Times
Breakthrough AML Treatment: Triple Drug Therapy Shows Complete Remission in Patients with Resistant Mutations - Stock Titan
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Comparing Sana Biotechnology (NASDAQ:SANA) & Aptose Biosciences (NASDAQ:APTO) - Defense World
Learn to Evaluate (APS) using the Charts (APS:CA) - news.stocktradersdaily.com
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
(APS) Equity Trading Insights (APS:CA) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
(APS) Investment Strategy and Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Announces Auditor Not Standing for Re-Appointment - The Manila Times
Major Red Flag: KPMG Abandons Aptose Over Complex Financial Instrument Controls - Stock Titan
Aptose Biosciences to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference - Nasdaq
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference - The Manila Times
Aptose Biosciences announces change in accounting firm By Investing.com - Investing.com India
Aptose Biosciences announces change in accounting firm - Investing.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com - Defense World
(APS) Daily Stock Insights (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (TSE:APS) Stock Price Passes Below 200-Day Moving Average – What’s Next? - The AM Reporter
Objective long/short (APS) Report (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
(APS) Technical Data (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences shares to delist from Nasdaq as of April 2 - Yahoo Finance
APTO stock touches 52-week low at $1.86 amid sharp annual decline - Investing.com Australia
APTO stock touches 52-week low at $1.86 amid sharp annual decline By Investing.com - Investing.com South Africa
Stock Market Shakes As Major Firms See Sharp Declines - Finimize
Aptose Biosciences Inc Stock (APTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):